Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Anna Prażmo

MD, MBiol


DPhil Student

Understanding the mechanisms by which molecular and phenotypic heterogeneity of MLL-rearranged infant ALL affects clinical outcome.

RESEARCH FOCUS

I joined the Roy Lab in October 2024 as a clinical DPhil in Cancer Science student under the supervision of Professor Andi Roy. My project is a part of Scientific Advances in Infant Leukaemia (SAIL), which aims to deliver a national clinical study that will provide unique insights into optimal treatment pathways for infant acute lymphoblastic leukaemia. We work to create a secure central database held at Oxford to capture demographic, diagnostic, molecular and clinical outcome data from sources such as NHS standard of care laboratory tests, multiomic analysis at the WIMM, as well as information gathered directly from parents. Another aim is a detailed characterisation of each patient's leukaemia to better understand disease biology and response to treatment, which can lead to better stratification and personalised medicine approach.

BACKGROUND

Before returning to Hertford College for the DPhil, I obtained a medical degree in Poland, and an integrated Master in Biology at Oxford, with a first-class thesis on the epidemiology of invasive meningococal disease. In 2024 I completed my foundation medical training, including an elective in paediatric haematooncology, which has been my long-standing interest.